Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07293832

Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction

The Impact of Sympathetic Drive Control With Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Aristotle University Of Thessaloniki · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established. Purpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI). Methods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization. Results: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.

Conditions

Timeline

Start date
2024-11-13
Primary completion
2026-06-01
Completion
2026-08-01
First posted
2025-12-19
Last updated
2025-12-19

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT07293832. Inclusion in this directory is not an endorsement.